Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: exosome therapeutics - ArunA Biomedical

Drug Profile

Research programme: exosome therapeutics - ArunA Biomedical

Latest Information Update: 11 Oct 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ArunA Biomedical
  • Developer ArunA Biomedical; Augusta University; University of Georgia
  • Class Exosome therapies; Neuroprotectants; Vascular disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Neurodegenerative disorders; Stroke

Highest Development Phases

  • Preclinical Traumatic brain injuries
  • Research Multiple sclerosis; Parkinson's disease
  • No development reported CNS disorders; Neurodegenerative disorders; Stroke

Most Recent Events

  • 06 Oct 2022 ArunA Biomedical announces intention to file IND for Stroke in second quarter of 2023
  • 14 Jun 2022 ArunA Biomedical and University of Georgia has patent protection for the composition of neural exosomes and their use as a therapeutic for neurological diseases and disorders in Japan
  • 31 May 2022 Preclinical trials in Traumatic brain injuries in USA (Parenteral)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top